[Therapeutic possibilities for polyomavirus infections in renal transplantation].
TO IMPROVE THERAPEUTIC MANAGEMENT: The aim is the early detection of polyomavirus infection, before the onset of tubulo-interstitial nephritic lesions, and to reduce viral replication. AT THE STAGE OF POLYOMAVIRUS INFECTION: Treatment relies on the reduction of immunosuppression. Efficacy is controlled by monitoring the decoy cells in the urine and the detection and quantification of the DNA of polyomaviruses in the plasma and urine. AT THE STAGE OF POLYOMAVIRUS DISEASE: The aim is to reduce the viral replication by further decreasing immunosuppression to stabilize renal function and avoid graft rejection. When signs of rejection and viral infection co-exist, cidofovir could be a therapeutic alternative. However, the use of cidofovir remains in the field of clinical research and requires the further development of therapeutic protocols.
Hurault de Ligny
Bruno
B
Service de néphrologie-transplantation rénale, CHU Clemenceau, Caen (14). huraultdeligny-b@chu-caen.fr
Godin
Michel
M
Lobbedez
Thierry
T
Etienne
Isabelle
I
El Haggan
Wael
W
Pujo
Myriam
M
Ryckelynck
Jean-Philippe
JP
D000998:Antiviral Agents / Q000627:therapeutic use*; D001739:BK Virus / Q000472:pathogenicity; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D007577:JC Virus / Q000472:pathogenicity; D016030:Kidney Transplantation / Q000009:adverse effects*; D009395:Nephritis, Interstitial / Q000188:drug therapy / Q000209:etiology / Q000821:virology; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D027601:Polyomavirus Infections / Q000188:drug therapy* / Q000209:etiology; D014779:Virus Replication
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir
Possibilités thérapeutiques des infections à polyomavirus humains en transplantation rénale.